منابع مشابه
liječenju zatajivanja srca Ivabradine in Heart failure Treatment
Poliklinika za prevenciju kardiovaskularnih bolesti i rehabilitaciju, Zagreb, Hrvatska Institute for Cardiovascular Prevention and Rehabilitation, Zagreb, Croatia SAŽETAK: Ivabradin je lijek za usporivanje srčane frekvencije, koji djeluje selektivnom i specifičnom inhibicijom If struje predvodnika srčanog ritma, koji regulira spontanu dijastoličku depolarizaciju u sinusnom čvoru i frekvenciju s...
متن کاملIvabradine (Corlanor) for Heart Failure.
Atrial fibrillation, bradycardia, and hypertension may occur in patients taking ivabradine. As demonstrated in clinical trials, 5.3% to 9% of patients will develop atrial fibrillation vs. 3.8% to 8% of patients treated with placebo (number needed to treat to harm = 55 to 100). Bradycardia will occur in 10% to 13% of patients, most notably in those with cardiac conduction disorders, a low restin...
متن کاملImpact of Ivabradine on Inflammatory Markers in Chronic Heart Failure
Background. Inflammation plays a crucial role in the progression of chronic heart failure (CHF). Ivabradine is known to reduce the morbidity and mortality of patients with CHF under certain conditions. Beyond the reduction of heart rate, only limited knowledge exists about potential anti-inflammatory effects of ivabradine that might contribute to its benefit in CHF. Thus, the present study aime...
متن کاملEconomic evaluation of ivabradine in the treatment of chronic heart failure in Greece
BACKGROUND The objective of our study was to assess the cost-effectiveness of ivabradine plus standard care (SoC) in chronic heart failure (CHF) patients with sinus rhythm and a baseline heart rate ≥ 75 b.p.m. in Greece, in comparison with current SoC alone. METHODS An existing cost-effectiveness model consisting of two health states, was adapted to the Greek health care setting. All clinical...
متن کاملIvabradine in stable coronary artery disease without clinical heart failure.
BACKGROUND An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more. METHODS We conducted a randomized, double-blind, placebo-controlled trial of ivabrad...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cardiologia Croatica
سال: 2015
ISSN: 1848-543X,1848-5448
DOI: 10.15836/ccar.2015.148